Piper Sandler raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $39 and keeps an Overweight rating on the shares following Q4 reporting as the company shifts its primary focus to regulatory approvals and commercial readiness. With a hat trick of positive pivotal data for bezuclastinib in 2025, the narrative turns to execution, says the firm. The NonAdvSM NDA has been submitted with acceptance expected this month, positioning the drug for potential approval and launch in the second half of 2026. Piper continues to recommend Cogent shares as the company de-risks its regulatory path and transitions to a commercial entity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
- Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
- Cogent Biosciences sees cash runway into 2028
- Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
- Cogent Biosciences announcse U.S. BTD for bezuclastinib